ESC 2026: ESC 2026: Head-to-head study compares inclisiran and bempedoic acid

Conferencepositiveinclisiranbempedoic acidPositive

AI Analysis

Summary

A head-to-head study presented at ESC 2026 demonstrated that inclisiran outperformed bempedoic acid in LDL-C lowering and target attainment, supporting its differentiation in high-risk patient populations.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Inclisiran outperformed bempedoic acid in LDL-C lowering and target attainment

Importance:5/10

Sentiment:

0.70

ESC 2026head-to-head comparisonLDL-C loweringcardiovascularlipid management

Related Companies

$NVS

Read the original article

Published by Clinical Trials Arena on August 31, 2026 9:01 PM

Read Original